Company: DHR
Filing Date: 2025-07-22
Form Type: 10-Q
Source: 0000313616-25-000153
Chunk: 147

Company: DANAHER CORP /DE/
Filing Date: 2025-07-22
Form: 10-Q
Item: Item 2
Chunk 147
---
-over-year sales volumes, partially offset by the impact of currency exchange rates and tariff costs.  The increase is also due to the impact of an acquisition-related charge recorded in the first half of 2024, net of the facility impairment recorded in the first half of 2025, both referenced above. 

OPERATING EXPENSES

Three-Month Period EndedSix-Month Period Ended($ in millions)June 27, 2025June 28, 2024June 27, 2025June 28, 2024Sales$5,936 $5,743 $11,677 $11,539 Selling, general and administrative expenses2,360 1,869 4,218 3,676 Research and development expenses403 391 782 759 SG&A as a % of sales39.8 %32.5 %36.1 %31.9 %R&D as a % of sales6.8 %6.8 %6.7 %6.6 %

32

SG&A expenses as a percentage of sales increased during both the three and six-month periods ended June 27, 2025 as compared to the comparable periods in 2024, primarily driven by the $432 million impairment charge related to a trade name in the Life Sciences segment recorded in the second quarter of 2025, and to a lesser extent, a year-over-year increase in costs incurred for productivity improvement actions, net of incremental year-over-year cost savings associated with continuing productivity improvement initiatives and cost structure improvements.  Refer to Note 8 to the accompanying Consolidated Condensed Financial Statements for additional information regarding the impairment. 

R&D expenses (consisting principally of internal and contract engineering personnel costs) as a percentage of sales remained essentially flat during both the three and six-month periods ended June 27, 2025 as compared to the comparable period of 2024, as increased R&D spending correlated to the increases in sales. 

OTHER INCOME (EXPENSE), NET 

For a description of the Company’s other income (expense), net during the three and six-month periods ended June 27, 2025 and June 28, 2024, refer to Note 7 to the accompanying Consolidated Condensed Financial Statements. 

INTEREST COSTS AND FINANCING 

For a discussion of the Company’s outstanding indebtedness, refer to Note 10 to the accompanying Consolidated Condensed Financial Statements.  

Interest expense of